Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

被引:443
|
作者
Liu, XQ [1 ]
Erikson, RL [1 ]
机构
[1] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
关键词
D O I
10.1073/pnas.1031523100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Elevated expression of mammalian polo-like kinase (PIk)1 occurs in many different types of cancers, and PIk1 has been proposed as a novel diagnostic marker for several tumors. We used the recently developed vector-based small interfering RNA technique to specifically deplete PIk1 in cancer cells. We found that PIk1 depletion dramatically inhibited cell proliferation, decreased viability, and resulted in cell-cycle arrest with 4 N DNA content. The formation of dumbbell-like chromatin structure suggests the inability of these cells to completely separate the sister chromatids at the onset of anaphase. PIk1 depletion induced apoptosis, as indicated by the appearance of subgenomic DNA in fluorescence-activated cell-sorter (FACS) profiles, the activation of caspase 3, and the formation of fragmented nuclei. PIk1-depletion-induced apoptosis was partially reversed by cotransfection of nondegradable mouse PIk1 constructs. In addition, the p53 pathway was shown to be involved in PIk1-depletion-induced apoptosis. DNA damage occurred in PIk1-depleted cells and inhibition of ATM strongly potentiated the lethality of PIk1 depletion. Although p53 is stabilized in PIk1-depleted cells, DNA damage also occurs in p53(-/-) cells. These data support the notion that disruption of PIk1 function could be an important application in cancer therapy.
引用
收藏
页码:5789 / 5794
页数:6
相关论文
共 50 条
  • [31] The polo-like kinase Plk2 is required for centrosome duplication in mammalian cells
    Warnke, S
    Hames, R
    Kemmler, S
    Hoffmann-Rohrer, UW
    Fry, A
    Hoffmann, I
    EUROPEAN JOURNAL OF CELL BIOLOGY, 2004, 83 : 79 - 79
  • [32] Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3
    Conn, CW
    Hennigan, RF
    Dai, W
    Sanchez, Y
    Stambrook, PJ
    CANCER RESEARCH, 2000, 60 (24) : 6826 - 6831
  • [33] MOLECULAR TARGETING OF POLO-LIKE KINASE 1 (PLK1) ELIMINATES MEDULLOBLASTOMA BRAIN TUMOUR CELLS
    Lee, Cathy
    Fotovati, Abbas
    Triscott, Joanna
    Dunn, Sandra
    NEURO-ONCOLOGY, 2012, 14 : 96 - 96
  • [34] Polo-like kinase 4 (Plk4) promotes cancer cell invasion
    Kazazian, Karineh
    Xu, Roland
    Zih, Francis
    Rosario, Carla
    Swallow, Carol J.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S128 - S128
  • [35] Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer
    Lashen, Ayat G.
    Toss, Michael S.
    Wootton, Louisa
    Green, Andrew R. R.
    Mongan, Nigel P.
    Madhusudan, Srinivasan
    Rakha, Emad
    HISTOPATHOLOGY, 2023, 83 (03) : 414 - 425
  • [36] Polo-like kinase 1 as target for cancer therapy
    Lily Weiß
    Thomas Efferth
    Experimental Hematology & Oncology, 1 (1)
  • [37] Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer
    Shao, Chen
    Ahmad, Nihal
    Hodges, Kurt
    Kuang, Shihuan
    Ratliff, Tim
    Liu, Xiaoqi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (04) : 2024 - 2033
  • [38] Overexpression of Polo-like kinase1 (PLK1) in chondrosarcoma and its implications for cancer progression
    Li, Kelu
    Ma, Hongmei
    Zheng, Xiuyan
    Hu, Yali
    Wang, Yue
    Zhang, Kunpeng
    Chen, Jiahan
    Qi, Yan
    Jiang, Jinfang
    Pang, Lijuan
    Tao, Lin
    Gu, Wenyi
    Li, Feng
    Zou, Hong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (03): : 1707 - 1711
  • [39] Polo-like kinase 1 as target for cancer therapy
    Weiss, Lily
    Efferth, Thomas
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2012, 1
  • [40] Targeting polo-like kinase 1 for cancer therapy
    Klaus Strebhardt
    Axel Ullrich
    Nature Reviews Cancer, 2006, 6 : 321 - 330